GLP-1 weight-loss drugs linked to lower cancer risk, higher testosterone, and less clotting
Daily Mail — Science—A wave of new research is expanding the known benefits of GLP-1 receptor agonist drugs, the class that includes Ozempic and Wegovy, well beyond weight loss. PBS NewsHour reported a study suggesting GLP-1 drugs may meaningfully reduce the risk of several cancers, adding to growing evidence of broad metabolic effects. Separate research found that GLP-1s lower the risk of dangerous blood clots and death in patients with autoimmune conditions. A third study found men taking GLP-1s showed increases in testosterone levels and improved sperm counts, raising new possibilities for male fertility treatment. The cumulative findings are pushing researchers and regulators to consider whether GLP-1s should be studied and potentially approved for indications far beyond obesity.
- Daily Mail — Science — Study links age at first sex to how people age
- Fox News — Fertility specialists are now examining whether GLP-1s could serve as a treatment for male infertility.
- Newsmax — GLP-1 drugs were linked to lower blood-clot risk and reduced mortality in patients with autoimmune diseases.
- Newsmax — Researchers found GLP-1 drugs boosted testosterone levels and sperm counts in male patients.
- PBS NewsHour — A new study found GLP-1 weight-loss drugs may also significantly reduce the risk of several cancers.